ID: h-b007ca967f
Hypothesis
Autophagy-Lysosomal Pathway Dysfunction as a Unifying Proteostasis Failure
Impaired autophagic flux and lysosomal degradation capacity represents a convergent failure point across AD, PD, ALS, and FTD.
EvidencePending (0%)📖 12 cit🗣 1 debates✓ 4 support✗ 3 oppose
⚠ Low Validation Senate Quality Gates →
🧪 Overview
Impaired autophagic flux and lysosomal degradation capacity represents a convergent failure point across AD, PD, ALS, and FTD. Multiple druggable nodes exist: TFEB activation, GBA1 enhancement, TMEM175 modulation, and VPS35/retromer stabilization. Cross-disease genetic evidence (GBA1, VPS35, TMEM175, SORL1) and postmortem tissue validation support this mechanism. Best near-term path is biomarker-enriched trials in GBA1-PD or prodromal carriers. CNS druggability remains the primary development barrier.
🧬 Mechanism
🔗 Mechanism from KG for TFEB, GBA1, VPS35, TMEM175
Auto-built from this analysis's top knowledge-graph edges.
graph TD
GBA1_mutations["GBA1 mutations"] -->|increases risk| PD["PD"]
TREM2_R47H_variant["TREM2 R47H variant"] -->|increases risk| Ad["Ad"]
alpha_synuclein_fibrils["alpha-synuclein fibrils"] -->|activates| NLRP3_Inflammasome["NLRP3 Inflammasome"]
TFEB_overexpression["TFEB overexpression"] -.->|inhibits| tau_A__pathology["tau/Aβ pathology"]
TARDBP_MUTATIONS["TARDBP MUTATIONS"] -->|causes| ALS_FTD["ALS/FTD"]
TDP_43_INCLUSIONS["TDP-43 INCLUSIONS"] -->|associated with| ALS_FTD_1["ALS/FTD"]
NfL_reduction["NfL reduction"] -->|biomarker for| als["als"]
TARDBP["TARDBP"] -->|cross disease mech| ALS["ALS"]
TARDBP_2["TARDBP"] -->|cross disease mech| FTD["FTD"]
TARDBP_3["TARDBP"] -->|cross disease mech| AD_LATE["AD/LATE"]
h_cross_synth_tdp43_rna_p["h-cross-synth-tdp43-rna-proteostasis"] -->|proposes shared me| TARDBP_4["TARDBP"]
SNCA["SNCA"] -->|cross disease mech| PD_5["PD"]
style GBA1_mutations fill:#ce93d8,stroke:#333,color:#000
style PD fill:#ef5350,stroke:#333,color:#000
style TREM2_R47H_variant fill:#ce93d8,stroke:#333,color:#000
style Ad fill:#ef5350,stroke:#333,color:#000
style alpha_synuclein_fibrils fill:#4fc3f7,stroke:#333,color:#000
style NLRP3_Inflammasome fill:#ce93d8,stroke:#333,color:#000
style TFEB_overexpression fill:#4fc3f7,stroke:#333,color:#000
style tau_A__pathology fill:#4fc3f7,stroke:#333,color:#000
style TARDBP_MUTATIONS fill:#ce93d8,stroke:#333,color:#000
style ALS_FTD fill:#ef5350,stroke:#333,color:#000
style TDP_43_INCLUSIONS fill:#4fc3f7,stroke:#333,color:#000
style ALS_FTD_1 fill:#ef5350,stroke:#333,color:#000
style NfL_reduction fill:#ce93d8,stroke:#333,color:#000
style als fill:#ef5350,stroke:#333,color:#000
style TARDBP fill:#4fc3f7,stroke:#333,color:#000
style ALS fill:#ef5350,stroke:#333,color:#000
style TARDBP_2 fill:#4fc3f7,stroke:#333,color:#000
style FTD fill:#ef5350,stroke:#333,color:#000
style TARDBP_3 fill:#4fc3f7,stroke:#333,color:#000
style AD_LATE fill:#ef5350,stroke:#333,color:#000
style h_cross_synth_tdp43_rna_p fill:#4fc3f7,stroke:#333,color:#000
style TARDBP_4 fill:#4fc3f7,stroke:#333,color:#000
style SNCA fill:#4fc3f7,stroke:#333,color:#000
style PD_5 fill:#ef5350,stroke:#333,color:#000⚖️ Evidence
⚖️ Evidence Matrix4 supports3 contradicts
Supports
Declining lysosomal enzyme activity documented across NDDs in human postmortem tissue
Contradicts
Selective autophagy knockouts rarely cause disease-specific proteinopathies, only neurodegeneration broadly
Contradicts
TMEM175 GWAS effect size modest (OR ~1.4-1.6), likely a modifier not core mechanism
Contradicts
Lysosomal enzyme declines are late-stage findings in postmortem tissue, cannot establish causation
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — TFEB
No curated PDB or AlphaFold mapping for TFEB yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TFEB, GBA1, VPS35, TMEM175.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 1.8%
Volatility
Low
0.0029
Events (7d)
3
Price History
▼22.1%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF TFEB nuclear translocation is induced via mTOR inhibition (rapamycin 2mg/kg i.p. 3x/week) in aged 3xTg-AD mice crossed with TMEM175 knockout mice for 12 weeks, THEN autophagic flux will increase (L | ≥40% reduction in insoluble phospho-tau (AT8) and normalized LC3-II/LC3-I ratio in cortical tissue within 12 weeks | — no observation — | pending | 0.61 |
| IF GBA1 activity is pharmacologically enhanced (e.g., with ambroxol 600-1200 mg/day) in GBA1-associated Parkinson's disease patients for 6 months, THEN CSF glucocerebrosidase activity will increase by | ≥30% increase in CSF GCase activity and ≥25% reduction in plasma α-synuclein (Simoa) within 6 months of treatment | — no observation — | pending | 0.72 |
🔮 Falsifiable Predictions (2)
pendingconf 72%
IF GBA1 activity is pharmacologically enhanced (e.g., with ambroxol 600-1200 mg/day) in GBA1-associated Parkinson's disease patients for 6 months, THEN CSF glucocerebrosidase activity will increase by ≥30% and plasma α-synuclein levels will decrease by ≥25% relative to placebo.
Predicted outcome: ≥30% increase in CSF GCase activity and ≥25% reduction in plasma α-synuclein (Simoa) within 6 months of treatment
Falsification: CSF GCase activity fails to increase by ≥30%, or plasma α-synuclein fails to decrease by ≥25%, or Unified Parkinson's Disease Rating Scale (UPDRS) Part III worsens by ≥5 points relative to placebo
pendingconf 61%
IF TFEB nuclear translocation is induced via mTOR inhibition (rapamycin 2mg/kg i.p. 3x/week) in aged 3xTg-AD mice crossed with TMEM175 knockout mice for 12 weeks, THEN autophagic flux will increase (LC3-II/LC3-I ratio normalizes, p62 degrades) and soluble tau/phospho-tau will decrease by ≥40% compar
Predicted outcome: ≥40% reduction in insoluble phospho-tau (AT8) and normalized LC3-II/LC3-I ratio in cortical tissue within 12 weeks
Falsification: LC3-II/LC3-I ratio remains elevated (indicating impaired autophagosome clearance), p62 accumulates, and tau/phospho-tau levels do not decrease by ≥40%, indicating TFEB activation is insufficient to re
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.